Clinically, the substantial increases in CX3CR1+/CD4+ T‐cells observed here are of particular note since inhibition of CX3CR1 to ameliorate atherosclerosis progression is promising,82, 83 as is CX3CR1 modulation in the treatment of CKD.84 This evidence concerns the gene CX3CR1 and atherosclerosis.